Efficacy of AC-T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis.

Int J Breast Cancer · 2026 · PMC13282549 · PMID 42328209

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant

The mean age was slightly higher in the AC‐T group (49.04 ± 11.86 years) compared with the TAC group (45.27 ± 9.14 years), and a similar trend was observed in BMI; however, these differences did not reach statistical significance ( p > 0.05).

also in 111,027 other papers

approached significanceno p-value reported

Once this imbalance was accounted for in the multivariable model, the regimen‐specific effect on survival was substantially attenuated and no longer approached significance.

also in 8,237 other papers

showed a trendno p-value reported

Specifically, TAC demonstrated a statistically significant advantage in DRFS at 10 years, whereas AC‐T showed a trend toward improved OS and early disease control, though not statistically significant. 4.2.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.